Skip to content

Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)

Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00760591
Enrollment
30
Registered
2008-09-26
Start date
2008-09-30
Completion date
Unknown
Last updated
2008-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Failure

Keywords

Acute kidney failure, Colonoscopy, Neutrophil gelatinase-associated lipocalin

Brief summary

Oral phosphate purgative is the preferred bowel regimen on the basis of better tolerability, cost effectiveness, and efficacy. There are also numerous reports of patients with even previously normal renal function developing acute and chronic kidney disease after use of oral phosphate purgative. Several uncontrolled case reports and case series suggest a potential link between oral phosphate and acute kidney injury and/or chronic kidney disease1. Its use is contraindicated in patients with preexisting renal disease because of the risk for developing acute renal failure, so called acute phosphate nephropathy, or electrolyte disturbance. Since most of the outpatients who are going to undergo a colonoscopy are exposed to this agent, it is important to detect or prevent vulnerable patients. We would seek a sensitive and rapid diagnosis method of acute kidney injury following sodium phosphate bowel preparation. Within a few hours, NGAL mRNA is highly upregulated after kidney injury, such as renal ischemia-reperfusion and cisplatin nephropathy, NGAL induction precedes the elevation of classical markers for kidney damage such as serum creatinine. The investigators will investigate the change of NGAL following sodium phosphate bowel preparation.

Interventions

None listed

Sponsors

Soon Chun Hyang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Exclusion criteria

* Who takes ACE-inhibitor, ARB * Has a renal or heart disease * Has a serum electrolyte disturbance

Design outcomes

Primary

MeasureTime frame
NGALBaseline, colonoscopy day, post 1day, post 2 day

Countries

South Korea

Contacts

Primary ContactSoon Hyo Kwon, MD
ksoonhyo@hosp.sch.ac.kr+8-02-709-9491

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026